304 related articles for article (PubMed ID: 26683520)
21. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
[TBL] [Abstract][Full Text] [Related]
22. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
Budhu S; Schaer DA; Li Y; Toledo-Crow R; Panageas K; Yang X; Zhong H; Houghton AN; Silverstein SC; Merghoub T; Wolchok JD
Sci Signal; 2017 Aug; 10(494):. PubMed ID: 28851824
[TBL] [Abstract][Full Text] [Related]
23. G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets.
Karagiannidis I; Jerman SJ; Jacenik D; Phinney BB; Yao R; Prossnitz ER; Beswick EJ
Front Immunol; 2020; 11():1885. PubMed ID: 33042110
[TBL] [Abstract][Full Text] [Related]
24. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
25. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-7 Modulates Anti-Tumor CD8+ T Cell Responses via Its Action on Host Cells.
Deiser K; Stoycheva D; Bank U; Blankenstein T; Schüler T
PLoS One; 2016; 11(7):e0159690. PubMed ID: 27447484
[TBL] [Abstract][Full Text] [Related]
27. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H
Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964
[TBL] [Abstract][Full Text] [Related]
28. Plasmacytoid dendritic cells play a key role in tumor progression in lipopolysaccharide-stimulated lung tumor-bearing mice.
Rega A; Terlizzi M; Luciano A; Forte G; Crother TR; Arra C; Arditi M; Pinto A; Sorrentino R
J Immunol; 2013 Mar; 190(5):2391-402. PubMed ID: 23355734
[TBL] [Abstract][Full Text] [Related]
29. T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.
Hu J; Sun C; Bernatchez C; Xia X; Hwu P; Dotti G; Li S
Clin Cancer Res; 2018 Jun; 24(12):2920-2934. PubMed ID: 29391351
[No Abstract] [Full Text] [Related]
30. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
31. Donor-antigen Inoculation in the Testis Promotes Skin Allograft Acceptance Induced by Conventional Costimulatory Blockade via Induction of CD8 + CD122+ and CD4 + CD25+ Regulatory T Cells.
Cong L; Wang SF; Zhao ZL; Yang RY
Transplantation; 2016 Apr; 100(4):763-71. PubMed ID: 26569069
[TBL] [Abstract][Full Text] [Related]
32. CD8+CD122+ regulatory T cells (Tregs) and CD4+ Tregs cooperatively prevent and cure CD4+ cell-induced colitis.
Endharti AT; Okuno Y; Shi Z; Misawa N; Toyokuni S; Ito M; Isobe K; Suzuki H
J Immunol; 2011 Jan; 186(1):41-52. PubMed ID: 21098236
[TBL] [Abstract][Full Text] [Related]
33. CD40 signaling in CD8+CD40+ T cells turns on contra-T regulatory cell functions.
Martin S; Pahari S; Sudan R; Saha B
J Immunol; 2010 May; 184(10):5510-8. PubMed ID: 20400702
[TBL] [Abstract][Full Text] [Related]
34. Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8
Lin L; Rayman P; Pavicic PG; Tannenbaum C; Hamilton T; Montero A; Ko J; Gastman B; Finke J; Ernstoff M; Diaz-Montero CM
Cancer Immunol Immunother; 2019 Mar; 68(3):395-405. PubMed ID: 30552459
[TBL] [Abstract][Full Text] [Related]
35. CD8
Han YK; Jin Y; Miao YB; Shi T; Lin XP
Inflammation; 2018 Oct; 41(5):1791-1803. PubMed ID: 29951876
[TBL] [Abstract][Full Text] [Related]
36. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
37. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
[TBL] [Abstract][Full Text] [Related]
38. Immune-mediated antitumor effect by type 2 diabetes drug, metformin.
Eikawa S; Nishida M; Mizukami S; Yamazaki C; Nakayama E; Udono H
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1809-14. PubMed ID: 25624476
[TBL] [Abstract][Full Text] [Related]
39. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma.
Effern M; Glodde N; Braun M; Liebing J; Boll HN; Yong M; Bawden E; Hinze D; van den Boorn-Konijnenberg D; Daoud M; Aymans P; Landsberg J; Smyth MJ; Flatz L; Tüting T; Bald T; Gebhardt T; Hölzel M
Immunity; 2020 Sep; 53(3):564-580.e9. PubMed ID: 32750334
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
